A practical update on the use of bortezomib in the management of multiple myeloma.
about
Boron chemicals in diagnosis and therapeuticsTrial Watch: Proteasomal inhibitors for anticancer therapyBerbamine, a novel nuclear factor kappaB inhibitor, inhibits growth and induces apoptosis in human myeloma cells.Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.Proteasome inhibitor bortezomib suppresses nuclear factor-kappa B activation and ameliorates eye inflammation in experimental autoimmune uveitisAcupuncture treatment for bortezomib-induced peripheral neuropathy: a case reportSubacute liver failure secondary to amyloid light-chain amyloidosis.Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapyProteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide)KSP inhibitor SB743921 induces death of multiple myeloma cells via inhibition of the NF-κB signaling pathway.Metabolic control of proteasome function.Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.Analysis of physicians' perspectives versus patients' preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma.Targeting NF-kappaB for colorectal cancer.Bortezomib for previously untreated multiple myeloma.Bortezomib for previously untreated multiple myeloma.Proteasome inhibitors in multiple myeloma: 10 years later.An analysis of the safety profile of proteasome inhibitors for treating various cancers.Synergistic action of 5Z-7-oxozeaenol and bortezomib in inducing apoptosis of Burkitt lymphoma cell line Daudi.Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells.Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.Role of bortezomib for the treatment of previously untreated multiple myeloma.The proteasome and proteasome inhibitors in multiple myeloma.Xanthohumol inhibits angiogenesis by suppressing nuclear factor-κB activation in pancreatic cancer.Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy.Bortezomib in multiple myelomaSynthesis of a Bone-Targeted Bortezomib with In Vivo Anti-Myeloma Effects in Mice
P2860
Q27006075-8A9E2E23-9D48-40D1-939E-A280B5567556Q28082910-7796D1E8-3D76-478F-8916-B5AB13577DCAQ30952817-77D6E176-29A6-4CB2-A58B-B5169C4A9B3EQ33632270-32703B3A-A00D-47A3-8DB7-85A123E5AD6AQ35012949-4F5D486E-5A34-49BF-9B02-1D87BA35D633Q35428713-101D1E8B-3BD5-495C-837A-C8E785FAE46AQ36002205-929B1E53-FB9B-4083-B6EA-E9ED6B88E8BDQ36251560-281FA9E0-FA1C-49B8-A275-8AAF9EEE9A53Q36502978-9181DD61-1146-4133-B655-827C4AC2B2C6Q37013815-3FBE10F7-1937-4D19-B1DE-755759355D80Q37029653-8F3D4BA6-2980-4202-9612-95A892A209F5Q37327618-AD374D85-4032-4267-9E2A-0AB34053C70EQ37682654-B1D007C9-FAA6-4F2F-9CF5-80FA8C1F05A5Q37724387-8077AF25-5237-4527-90C2-3C8CBE1C009EQ37908155-E676FFDE-1C6E-4562-9D4E-FC43DFCFB3D7Q37937699-A475B954-123D-4FB8-BC2A-584D94EB2012Q38014395-CF88C88D-E16E-45BA-AD41-3E4D6ECD9274Q38227506-3FE8D65E-BE77-4F27-877D-F1316244635FQ38847744-4EFFC55D-DACA-4BE9-B860-84E593386C08Q39184945-171368E3-6FB5-47E7-99C8-3395CE07E35AQ39298317-06379D93-04C1-4A1C-90E0-DB2FCF4341F7Q40134056-F2FC7117-CEF0-4AEA-8114-85F09A510362Q40333043-63AFF367-2327-4771-8AAE-54BF1ECB05C4Q42807448-ED724B12-8232-4A9E-97BE-EDEBB69DA2F7Q47339695-5813B5D0-9920-4C2F-99CF-8BEE442A9CB2Q47420926-E2BF5C05-D8B7-47AA-9C2A-D98602EA34AEQ50894105-83249F41-D8A8-4B65-9BEB-F3E03F0C2C13Q57904731-54CDF718-E911-435C-B2EC-E4B1A214CB0EQ58753490-D489DD40-C812-439B-B57A-0D84E54CC087
P2860
A practical update on the use of bortezomib in the management of multiple myeloma.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
A practical update on the use of bortezomib in the management of multiple myeloma.
@ast
A practical update on the use of bortezomib in the management of multiple myeloma.
@en
type
label
A practical update on the use of bortezomib in the management of multiple myeloma.
@ast
A practical update on the use of bortezomib in the management of multiple myeloma.
@en
prefLabel
A practical update on the use of bortezomib in the management of multiple myeloma.
@ast
A practical update on the use of bortezomib in the management of multiple myeloma.
@en
P2093
P50
P1433
P1476
A practical update on the use of bortezomib in the management of multiple myeloma.
@en
P2093
Axel Glasmacher
Jamie Cavenagh
Jesús San Miguel
Joan Bladé
Mario Boccadoro
Sundar Jagannath
P356
10.1634/THEONCOLOGIST.11-1-51
P577
2006-01-01T00:00:00Z